132 related articles for article (PubMed ID: 31755143)
21. S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C melanoma.
Wevers KP; Kruijff S; Speijers MJ; Bastiaannet E; Muller Kobold AC; Hoekstra HJ
Ann Surg Oncol; 2013 Aug; 20(8):2772-9. PubMed ID: 23512078
[TBL] [Abstract][Full Text] [Related]
22. Serum LDH values in childhood acute leukemias and non-Hodgkin's lymphoma.
Suarez CR; Andreeff M; Miller DR
Med Pediatr Oncol; 1984; 12(2):89-92. PubMed ID: 6583472
[TBL] [Abstract][Full Text] [Related]
23. Serum lactate dehydrogenase is a predictor of poor survival in malignant melanoma.
Gao D; Ma X
Panminerva Med; 2017 Dec; 59(4):332-337. PubMed ID: 27309261
[TBL] [Abstract][Full Text] [Related]
24. Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis.
Petrelli F; Ardito R; Merelli B; Lonati V; Cabiddu M; Seghezzi S; Barni S; Ghidini A
Melanoma Res; 2019 Feb; 29(1):1-12. PubMed ID: 30308577
[TBL] [Abstract][Full Text] [Related]
25. The role of serum lactate dehydrogenase level as a prognostic indicator in resected, high risk melanoma.
Kumar AB; Aguilera JV; Velazquez A; Yan Y; Jakub J; Brewer J; Hieken T; Block M; McWilliams R; Otley C; Markovic S; Kottschade L
Dermatol Ther; 2019 Mar; 32(2):e12813. PubMed ID: 30620137
[No Abstract] [Full Text] [Related]
26. Prognostic score for patients with advanced melanoma treated with ipilimumab.
Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
[TBL] [Abstract][Full Text] [Related]
27. Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomas.
Ferraris AM; Giuntini P; Gaetani GF
Blood; 1979 Oct; 54(4):928-32. PubMed ID: 476306
[TBL] [Abstract][Full Text] [Related]
28. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma.
Vonderheid EC; Zhang Q; Lessin SR; Polansky M; Abrams JT; Bigler RD; Wasik MA
J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):207-20. PubMed ID: 9486676
[TBL] [Abstract][Full Text] [Related]
29. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951).
Agarwala SS; Keilholz U; Gilles E; Bedikian AY; Wu J; Kay R; Stein CA; Itri LM; Suciu S; Eggermont AM
Eur J Cancer; 2009 Jul; 45(10):1807-14. PubMed ID: 19419855
[TBL] [Abstract][Full Text] [Related]
30. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma.
Franzke A; Probst-Kepper M; Buer J; Duensing S; Hoffmann R; Wittke F; Volkenandt M; Ganser A; Atzpodien J
Br J Cancer; 1998 Jul; 78(1):40-5. PubMed ID: 9662248
[TBL] [Abstract][Full Text] [Related]
31. High serum galectin-3 in advanced melanoma: preliminary results.
Vereecken P; Zouaoui Boudjeltia K; Debray C; Awada A; Legssyer I; Sales F; Petein M; Vanhaeverbeek M; Ghanem G; Heenen M
Clin Exp Dermatol; 2006 Jan; 31(1):105-9. PubMed ID: 16309497
[TBL] [Abstract][Full Text] [Related]
32. Results of the determination of serum markers in patients with malignant melanoma.
Lugović L; Situm M; Buljan M; Poduje S; Sebetić K
Coll Antropol; 2007 Jan; 31 Suppl 1():7-11. PubMed ID: 17469741
[TBL] [Abstract][Full Text] [Related]
33. An analysis of lactate dehydrogenase (LDH) levels in advanced stage IV melanoma of the skin: prognostic capabilities and demographic variability.
Desai AD; Chinta S; Yeh C; Shah VP; Shah R; Paskhover B; Schwartz RA
Arch Dermatol Res; 2023 May; 315(4):799-806. PubMed ID: 36318305
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-6 and its surrogate C-reactive protein are useful serum markers for monitoring metastasized malignant melanoma.
Deichmann M; Benner A; Waldmann V; Bock M; Jäckel A; Näher H
J Exp Clin Cancer Res; 2000 Sep; 19(3):301-7. PubMed ID: 11144523
[TBL] [Abstract][Full Text] [Related]
35. LDH and melanoma.
Finck SJ; Giuliano AE; Morton DL
Cancer; 1983 Mar; 51(5):840-3. PubMed ID: 6821850
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of serum lactic dehydrogenase in non-Hodgkin's lymphoma.
Hagberg H; Siegbahn A
Scand J Haematol; 1983 Jul; 31(1):49-56. PubMed ID: 6867608
[TBL] [Abstract][Full Text] [Related]
37. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients.
Sanmamed MF; Fernández-Landázuri S; Rodríguez C; Lozano MD; Echeveste JI; Pérez Gracia JL; Alegre E; Carranza O; Zubiri L; Martín-Algarra S; González A
Clin Chim Acta; 2014 Feb; 429():168-74. PubMed ID: 24333389
[TBL] [Abstract][Full Text] [Related]
38. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma.
Hamberg AP; Korse CM; Bonfrer JM; de Gast GC
Melanoma Res; 2003 Feb; 13(1):45-9. PubMed ID: 12569284
[TBL] [Abstract][Full Text] [Related]
39. Circulating melanoma cells as a potential biomarker to detect metastasis and evaluate prognosis.
Hida T; Yoneta A; Wakamatsu K; Yanagisawa K; Ishii-Osai Y; Kan Y; Kato J; Yamashita T
Australas J Dermatol; 2016 May; 57(2):145-9. PubMed ID: 26931184
[TBL] [Abstract][Full Text] [Related]
40. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.
Schmidt H; Johansen JS; Gehl J; Geertsen PF; Fode K; von der Maase H
Cancer; 2006 Mar; 106(5):1130-9. PubMed ID: 16456816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
